This should be trading much closer to cash value. Because they are going to spend all that cash in the Phase III trial, and the gamble is that they can (at least) make it back again. I'm very skeptical that this drug will make much of an impact, and that's even before you consider the intense competition in this market segment.
The market should see sense, and send this lower.
This should be trading much closer to cash value. Because they...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)